TriSalus Life Sciences (TLSI) Projected to Release Quarterly Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect TriSalus Life Sciences to announce earnings of ($0.1550) per share and revenue of $10.2670 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

TriSalus Life Sciences Stock Down 2.2%

NASDAQ:TLSI traded down $0.11 during mid-day trading on Tuesday, hitting $4.64. The stock had a trading volume of 44,696 shares, compared to its average volume of 303,528. The company has a market capitalization of $285.22 million, a PE ratio of -3.29 and a beta of 0.43. The company has a current ratio of 5.78, a quick ratio of 5.46 and a debt-to-equity ratio of 2.58. The stock has a 50-day simple moving average of $4.03 and a two-hundred day simple moving average of $4.32. TriSalus Life Sciences has a twelve month low of $2.20 and a twelve month high of $7.95.

Wall Street Analysts Forecast Growth

TLSI has been the topic of several research reports. Lake Street Capital lowered their price objective on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Weiss Ratings lowered TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.50.

Insider Buying and Selling

In other news, Director Michael P. Stansky acquired 410,000 shares of TriSalus Life Sciences stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $2.50 per share, for a total transaction of $1,025,000.00. Following the completion of the transaction, the director directly owned 1,240,722 shares in the company, valued at approximately $3,101,805. This trade represents a 49.35% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Mary T. Szela bought 39,682 shares of the company’s stock in a transaction on Friday, May 15th. The shares were acquired at an average price of $2.59 per share, for a total transaction of $102,776.38. Following the transaction, the chief executive officer directly owned 1,065,215 shares in the company, valued at $2,758,906.85. This trade represents a 3.87% increase in their position. The disclosure for this purchase is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders bought 719,682 shares of company stock valued at $1,804,176 over the last ninety days. Corporate insiders own 16.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Nantahala Capital Management LLC acquired a new position in TriSalus Life Sciences during the second quarter worth about $10,900,000. Vanguard Group Inc. boosted its stake in shares of TriSalus Life Sciences by 42.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock worth $5,392,000 after acquiring an additional 345,186 shares in the last quarter. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of TriSalus Life Sciences by 32.1% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock worth $5,957,000 after acquiring an additional 265,618 shares in the last quarter. Geode Capital Management LLC increased its stake in TriSalus Life Sciences by 107.4% in the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock valued at $2,480,000 after purchasing an additional 235,627 shares in the last quarter. Finally, Kotler Kevin acquired a new position in TriSalus Life Sciences during the fourth quarter worth $1,013,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.